Improving Colon Cancer Prognosis Prediction
Part of Cancer, Digestive system clinical trials.
This study looks at ways to better predict how colon cancer will behave after surgery. By understanding your cancer better, doctors hope to tailor treatment and follow-up, which could improve your outcome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a newly diagnosed colon cancer that has not spread to other organs
- You are scheduled for surgery to remove the tumor
- You have not had chemotherapy, radiation, or other cancer treatments for this cancer yet
- You do not have rectal cancer or more than one colon tumor at the same time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a simple blood test to look for tiny bits of tumor DNA after colon cancer surgery. If found, it may help doctors catch any remaining cancer early and guide further treatment.
This study tests whether giving additional (adjuvant) chemotherapy based on a special blood test—circulating tumor DNA (ctDNA)—can lower the risk of colon cancer coming back. It targets people with stage II–III colon cancer whose blood test is positive for minimal residual disease (MRD) after completing standard chemo.
This study looks at whether measuring certain blood markers can help track how well treatment is working in people with stage III colon cancer. It may help doctors understand if the cancer is responding to therapy before surgery.
This study measures “minimal residual disease,” meaning tiny amounts of cancer that may remain after surgery, using blood samples. It may help doctors better detect who is at higher risk of cancer coming back and guide follow-up care.
This trial tests whether a blood test that looks at cancer DNA can help decide whether you need “adjuvant” (extra) chemotherapy after colon cancer surgery. It may help some patients avoid unnecessary chemotherapy while still keeping the cancer from coming back.
This study looks for blood/tumor signals (“biomarkers”) that may help predict outcomes in people whose colorectal cancer returns and spreads after surgery. It mainly helps researchers understand who may do better or worse, which can guide future care.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.